Isocitrate Dehydrogenase (IDH) Inhibitors Industry Evaluation by Type, Molecule Categories, Delivery Method, and Region Through 2035
Overview:
The global isocitrate dehydrogenase (IDH) inhibitors market is poised for substantial expansion, driven by the increasing prevalence of IDH-mutant cancers and advancements in targeted therapies. In 2025, the market is anticipated to reach a valuation of USD 4.2 billion, reflecting the growing adoption of IDH inhibitors in clinical practice.
With a projected compound annual growth rate (CAGR) of 32%, the market is expected to surge to USD 104.8 billion by 2035. This growth trajectory is underpinned by the rising demand for effective therapies targeting IDH mutations across various cancer types, including acute myeloid leukemia (AML) and glioma.
Ongoing research and development efforts are focused on expanding the application of IDH inhibitors to other cancers, further fueling market growth. The oral route of administration is expected to dominate due to its convenience and ease of use, enhancing patient compliance and treatment outcomes.
Regionally, North America currently holds the largest market share, attributed to the high prevalence of cancer and advanced healthcare infrastructure. However, Asia Pacific is anticipated to exhibit the highest growth rate, driven by increasing healthcare expenditure and a rising cancer.
Key market players are engaged in strategic collaborations and acquisitions to strengthen their market presence and pipeline. These activities are crucial for sustaining competitiveness and meeting the evolving needs of the oncology landscape.
The market’s future is also shaped by regulatory approvals and the introduction of novel IDH inhibitors. These factors will continue to influence the adoption and accessibility of IDH-targeted therapies worldwide.
Year On Year Growth Chart
“`html
| Report Attribute | Details |
|---|---|
| Market Size in 2025 | USD 4.00 billion |
| Revenue Forecast for 2035 | USD 103.6 billion |
| Growth Rate (CAGR) | 33% from 2025 to 2035 |
| Base Year for Estimation | 2024 |
| Historical Data | N/A |
| Forecast Period | 2025 – 2035 |
| Quantitative Units | Revenue in USD billion and CAGR from 2025 to 2035 |
| Report Coverage | Revenue forecast, market share analysis, competitive landscape, growth drivers, and trends |
| Covered Segments | Type, molecule types, route of administration, and region |
| Regional Scope | North America, Europe, Asia Pacific |
| Country Scope | U.S., U.K., Germany, France, Italy, South Korea, Japan, China |
| Key Companies Analyzed | Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc., Sun Pharmaceutical Industries Ltd. |
| Customization Options | Free report customization (up to 8 analysts working days) with purchase. Changes to country, regional, and segment scope |
| Pricing and Purchase Options | Customizable purchase options for tailored research needs |
“`
Key Companies Market Share
Report Coverage & Deliverables
- Market Trends And Dynamics
- Competitve Benchmarking
- Historical data and forecasts
- Value/Volume analysis
- Company revenue shares and key strategies
- Regional opportunities
This is an indicative segmentation. Please request a sample report to see detail segmentation of this market.
Detailed Market Segmentation
- By Type
- R-132 Inhibitors
- R-179 Inhibitors
- By Molecule Types
- Small Molecules
- Peptides
- By Route of Administration
- Oral
- Intravenous
- Subcutaneous
- By Cancer Type
- Acute Myeloid Leukemia (AML)
- Glioma
- Chondrosarcoma
- Other Cancers
- By Region
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy)
- Asia Pacific (China, Japan, South Korea)
Table of Content
- Executive Summary
- Market Overview
- Key Market Dynamics
- Isocitrate Dehydrogenase (IDH) Inhibitors Market Analysis, by Type
- R-132 Inhibitors
- R-179 Inhibitors
- Isocitrate Dehydrogenase (IDH) Inhibitors Market Analysis, by Molecule Types
- Small Molecules
- Peptides
- Isocitrate Dehydrogenase (IDH) Inhibitors Market Analysis, by Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Isocitrate Dehydrogenase (IDH) Inhibitors Market Analysis, by Cancer Type
- Acute Myeloid Leukemia (AML)
- Glioma
- Chondrosarcoma
- Other Cancers
- Market Analysis, by Region
- North America
- Europe
- Asia Pacific
- North America Market Analysis
- Europe Market Analysis
- Asia Pacific Market Analysis
- Market Opportunity Assessment
- Market Competitive Landscape
- Company Market Share Analysis
- Strategic Developments
- Key Company Profiles
- Bayer
- Agios Pharma
- Daiichi Sankyo
- Ohm Oncology
- Celgene
- Philogen S.p.A.
- Tragara
- Aslan Pharmaceuticals
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Market Forecast and Projections
- Regulatory Framework
- Research Methodology